title: Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
abstract: Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.
authors.affiliation: National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264 USA. hassanr@mail.nih.gov
authors.forename: R
authors.initials: R
authors.lastname: Hassan
authors.forename: R
authors.initials: R
authors.lastname: Alexander
authors.forename: K
authors.initials: K
authors.lastname: Antman
authors.forename: P
authors.initials: P
authors.lastname: Boffetta
authors.forename: A
authors.initials: A
authors.lastname: Churg
authors.forename: D
authors.initials: D
authors.lastname: Coit
authors.forename: P
authors.initials: P
authors.lastname: Hausner
authors.forename: R
authors.initials: R
authors.lastname: Kennedy
authors.forename: H
authors.initials: H
authors.lastname: Kindler
authors.forename: M
authors.initials: M
authors.lastname: Metintas
authors.forename: L
authors.initials: L
authors.lastname: Mutti
authors.forename: M
authors.initials: M
authors.lastname: Onda
authors.forename: H
authors.initials: H
authors.lastname: Pass
authors.forename: A
authors.initials: A
authors.lastname: Premkumar
authors.forename: V
authors.initials: V
authors.lastname: Roggli
authors.forename: D
authors.initials: D
authors.lastname: Sterman
authors.forename: P
authors.initials: P
authors.lastname: Sugarbaker
authors.forename: R
authors.initials: R
authors.lastname: Taub
authors.forename: C
authors.initials: C
authors.lastname: Verschraegen
mesh_terms: D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008654:Mesothelioma / Q000453:epidemiology / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D009316:National Institutes of Health (U.S.); D010534:Peritoneal Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D014481:United States